Platelet-Rich Plasma Injections
Customize your policy alerts
Sign up for wellfleet Policy GL-019 alerts
Get alerted when Policy GL-019 changes without checking for updates manually.
Monitor payer policy activity
Describes how Wellfleet evaluates and reviews platelet-rich plasma utilization for specified orthopedic and musculoskeletal conditions for providers submitting claims for covered Wellfleet plan members.
No material clinical or coverage changes in this revision.
PRP Utilization Review Criteria
Investigational or Experimental Indications
The following listed PRP uses are designated investigational/experimental, either categorically or for the specified use or condition.
ALL of the following
- Achilles tendinopathy — investigational/experimental.
- Achilles rupture — investigational/experimental; surgical treatment is required for Achilles tendon rupture.
- Anterior cruciate ligament injury or reconstruction when used intra-operatively for surgical ACL reconstruction — investigational/experimental.
- Knee injections for osteoarthritis — investigational/experimental.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.